Diabetes, Cardiovascular & Renal Complications

Venue: Copthorne Tara Hotel

Location: London, United Kingdom

Event Date/Time: Nov 28, 2012 End Date/Time: Nov 29, 2012
Report as Spam



Our distinguished faculties unite the fields of pharmacology,
nanotechnology and clinical medicine to target atherosclerosis,
endothelial inflammation and end-stage renal disease. SMi's unique
program brings together the latest research from those at the forefront
of attenuating the complications arising from hyperglycaemia,
dyslipidaemia, and angiopathy.

Benefits of attending include:

Receive updates on novel GLP1 receptor agonists, SGLT2 and DPP-4

Review clinical results from the DEMAND study

Utilise biomarkers and imaging for the development of novel
cardiovascular and renal therapies

Evaluate new targets to reduce hypertension, hyperkalaemia and
endothelial inflammation

Ensure compliance with new FDA and EU guidelines when conducting
risk-benefit assessments

Key speakers include:

Riccardo Perfetti, Vice President Global Medical Affairs, Diabetes
Division, Sanofi-Aventis

Hans-Jürgen Wörle, Vice President & Therapeutic Area Head
Metabolism, Clinical Development and Medical Affairs,

James F. List, Vice President, Full Development, Bristol-Myers Squibb

Martin Simán, Director, Design and Interpretation Centre of Excellence,

Phil Ambery, Medical Director, Cardiovascular and Metabolic
R&D, GlaxoSmithKline

Bruce L. Riser, Director, Pharmaceuticals and Solutions, Medical
Products Division, Baxter Healthcare


Scardsale Place, Kensington
United Kingdom

Additional Information

Plus an interactive pre–conference workshop Tuesday 27th November 2012, The Copthorne Tara Hotel, London Cardio-renal risk in type 2 diabetes information from clinical trials: What we have, what do we need to know? Workshop leader: Luigi Gnudi, Professor of Diabetes and Metabolic Medicine, Honorary Consultant in Diabetes and Endocrinology, Head, Unit for Metabolic Medicine, Cardiovascular Division, King’s College London 1.30pm-5.30pm